EMA Recommends New Measures For JAK Inhibitors After Confirming Serious Risks

 
• By Neena Brizmohun

The sponsors of five EU-approved Janus kinase inhibitors for inflammatory conditions will have to update their product information to reflect new measures and warnings from the European Medicines Agency.

Drug warning label
The EMA has been exploring side effects associated with certain JAK inhibitors • Source: Shutterstock

More from Europe

More from Geography